A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
ObjectiveThe objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.MethodsTo gather comprehensive and reliable data for our analysis, we systematically searched multiple databas...
Saved in:
| Main Authors: | Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1472407/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
by: Benlong Yang, et al.
Published: (2025-05-01) -
Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01) -
PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01) -
Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01) -
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)